Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463797 | 0.92 | HTT (0.63) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| Benzyl Phenethylcarbamate SCHEMBL4287199 | 0.91 | LMNA (0.73) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL937184 | 0.90 | HTT (0.62) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL6558232 | 0.89 | SMN1; SMN2 (0.58) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL6554125 | 0.88 | LMNA (0.65) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL205765 | 0.87 | MGLL (0.65) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| Benzyl Phenethylcarbamate SCHEMBL6392045 | 0.86 | LMNA (0.67) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL8803823 | 0.86 | SMN1; SMN2 (0.76) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL8802503 | 0.85 | LMNA (0.61) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9487307 | 0.85 | LMNA (0.61) | LMNASMN1; SMN2HTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| EP-1378247-B1 | VISUAL FUNCTION DISORDER IMPROVING AGENTS | SENJU PHARMA CO (JP) | 2016-08-24 | — | — | EP | disclosed |
| CN-103796992-B | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2016-04-27 | — | — | CN | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| CN-102060780-B | Preparation method of 2-(N-substituted).-aminobenzimidazole derivative | ABA CHEMICALS SUZHOU LTD | 2014-11-05 | — | — | CN | disclosed |
| EP-2350020-B1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2757093-A1 | GUANIDINOBENZOIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1391454-B1 | Substituted benzamide compounds with antihypertensive activity | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011119559-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
| EP-0757038-B1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1195372-A1 | N-heterocyclic substituted benzamide derivatives with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2002-04-10 | — | — | EP | disclosed |
| US-6156766-A | Benzamide compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-5958944-A | TREATMENT OF CIRCULATORY DISEASES IN CORONARY, CEREBRAL, RENAL AND PERIPHERAL ARTERIES, AS A THERAPEUTIC AGENT FOR HYPERTENSION, ANGINA PECTORIS, AND RENAL AND PERIPHERAL CIRCULATION DISORDER, ANTIASTHMATIC AGENT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0643072-B1 | 2-Piperazinone compounds and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-02-24 | — | — | EP | disclosed |
| EP-0757038-A1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
| US-5550131-A | ANTITHROMBOTIC AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-27 | — | — | US | disclosed |
| EP-0643072-A1 | 2-Piperazinone compounds and their use | Takeda Chemical Industries, Ltd. (JP) | 1995-03-15 | — | — | EP | disclosed |
| EP-0306861-A2 | Stabilisation of chlorofluoroalkanes | Kali-Chemie Aktiengesellschaft (DE) | 1989-03-15 | — | — | EP | disclosed |
| EP-0298135-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | LMNA 1733/4885SMN1; SMN2 1384/4885HTT 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.